Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H28N2O |
Molecular Weight | 312.4491 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C(CN1CCCCC1)C#CC2=CC(CN3CCOCC3)=CC=C2
InChI
InChIKey=HDRIBIYPLKZUDQ-UHFFFAOYSA-N
InChI=1S/C20H28N2O/c1-3-10-21(11-4-1)12-5-2-7-19-8-6-9-20(17-19)18-22-13-15-23-16-14-22/h6,8-9,17H,1,3-5,10-16,18H2
Molecular Formula | C20H28N2O |
Molecular Weight | 312.4491 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19345233
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19345233
JNJ-10181457 is a histamine H3 receptor antagonist, which was developed by Johnson & Johnson. Selective blockade of histamine H3 receptors might have therapeutic utility for the treatment of working memory deficits and learning disorders, especially those in which ACh neurotransmission is compromised.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19345233
Curator's Comment: Known to be CNS penetrant in rats. Human data not available
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL264 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19345233 |
1.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. | 2009 Jun |
|
Diamine-based human histamine H3 receptor antagonists: (4-aminobutyn-1-yl)benzylamines. | 2009 Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19345233
in rats: A single administration of 10 mg/kg
Route of Administration:
Intraperitoneal
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 08:36:14 GMT 2023
by
admin
on
Sat Dec 16 08:36:14 GMT 2023
|
Record UNII |
JD270971QC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9944610
Created by
admin on Sat Dec 16 08:36:14 GMT 2023 , Edited by admin on Sat Dec 16 08:36:14 GMT 2023
|
PRIMARY | |||
|
544707-19-9
Created by
admin on Sat Dec 16 08:36:14 GMT 2023 , Edited by admin on Sat Dec 16 08:36:14 GMT 2023
|
PRIMARY | |||
|
1188547-18-3
Created by
admin on Sat Dec 16 08:36:14 GMT 2023 , Edited by admin on Sat Dec 16 08:36:14 GMT 2023
|
SUPERSEDED | |||
|
JD270971QC
Created by
admin on Sat Dec 16 08:36:14 GMT 2023 , Edited by admin on Sat Dec 16 08:36:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |